AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
Go back to AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting| AbbVie (NYSE: ABBV) | Delayed: 233.54 +3.53 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $232.97 | 52 Week Low | $50.71 | |||
| Day High | $234.95 | P/E | 50.66 | |||
| Day Low | $231.30 | EPS | $4.61 | |||
| Volume | 4,124,095 | |||||
